Philip Jull

Philip Jull

Chairman at ARROW EXPLORATION CORP.

Net worth: 2 M $ as of 2024-04-29

64 year
Consumer Services
Finance
Non-Energy Minerals

Profile

Mr. Philip G.
Jull, CFA MBA, is an Independent Director at GeneTether Therapeutics, Inc., a Chairman at Tryp Therapeutics, Inc. and an Executive Chairman at Arrow Exploration Corp.
He is on the Board of Directors at Tryptamine Therapeutics Ltd., GeneTether Therapeutics, Inc. and GeneTether, Inc. Mr. Jull was previously employed as an Independent Director by Aldridge Minerals, Inc., a Chairman by Bordeaux Capital, Inc., and a Managing Director-Corporate Finance by Mackie Research Capital Corp.
He received his undergraduate degree from the University of Toronto and an MBA from the University of Western Ontario.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-04-28 5,993,508 ( 2.10% ) 2 M $ 2024-04-29
2024-01-08 463,829 ( 0.48% ) 21 800 $ 2024-04-29
2023-03-06 148,919 ( 0.39% ) 6 701 $ 2024-04-29

Philip Jull active positions

CompaniesPositionStart
ARROW EXPLORATION CORP. Chairman 2020-03-20
TRYPTAMINE THERAPEUTICS LIMITED Chairman -
GENETETHER THERAPEUTICS INC. Director/Board Member 2021-09-30
Director/Board Member -
All active positions of Philip Jull

Former positions of Philip Jull

CompaniesPositionEnd
Founder 2021-12-31
Corporate Officer/Principal 2015-10-31
ALDRIDGE MINERALS INC. Director/Board Member -
See the detail of Philip Jull's experience

Training of Philip Jull

University of Toronto Undergraduate Degree
University of Western Ontario Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Philip Jull's experience

Connections

100 +

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
ARROW EXPLORATION CORP.

Energy Minerals

Private companies6

Non-Energy Minerals

Finance

Finance

Health Technology

Commercial Services

GeneTether Therapeutics, Inc.

See company connections